Tempus AI shares traded higher as investors reacted to a newly expanded, multi-year collaboration with Gilead Sciences aimed at powering cancer discovery work, a headline that has kept attention on Tempus’ data-and-AI platform beyond its core diagnostics business. The renewed deal narrative is helping offset recent choppiness in the stock by giving traders a clearer “platform monetization” catalyst tied to pharma R&D budgets. (benzinga.com)

The market’s key debate on Tempus has been whether Data & Applications can scale fast enough to create durable operating leverage. The Gilead expansion reinforces the strategic-collaboration thesis by emphasizing multi-year enterprise relationships that can layer on recurring revenue streams and increase utilization of Tempus’ proprietary multimodal dataset and analytics stack. (ainvest.com)

Alongside the partnership headline, investors are revisiting Tempus’ 2026 targets laid out in its corporate materials: approximately $1.59 billion in revenue (about 25% year-over-year growth) and approximately $65 million of adjusted EBITDA, with Q1 revenue targeted around $345 million. Tempus has also highlighted record total remaining contract value above $1.1 billion, with about $350 million tied to 2026, which management frames as improving forward revenue visibility. (cdn.prod.nntech.io)

Near-term, the next catalyst is the company’s upcoming financial update (market calendars point to early May), which traders will use to validate whether the expanded pharma collaboration is translating into accelerating Data & Applications growth and sustained oncology momentum. Any incremental disclosure around the contract scope, timing of revenue recognition, or additional strategic collaborations could amplify the move; conversely, limited near-term financial contribution could cool the rally. (benzinga.com)